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ABSTRACT 
Aim: Evidence of a possible connection between gut microbiota and several physiological 
processes linked to type 2 diabetes is increasing. However, the effect of multi-strain 
probiotics in people with type 2 diabetes remains unclear. This study investigated the effect 
of multi-strain microbial cell preparation—also refers to multi-strain probiotics—on glycemic 
control and other diabetes-related outcomes in people with type 2 diabetes. Design: A 
randomized, double-blind, parallel-group, controlled clinical trial. Setting: Diabetes clinic of 
a teaching hospital in Kuala Lumpur, Malaysia. Participants: A total of 136 participants with 
type 2 diabetes, aged 30–70 years, were recruited and randomly assigned to receive either 
probiotics (n = 68) or placebo (n = 68) for 12 weeks. Outcomes: Primary outcomes were 
glycemic control-related parameters, and secondary outcomes were anthropomorphic 
variables, lipid profile, blood pressure and high-sensitivity C-reactive protein. The 
Lactobacillus and Bifidobacterium quantities were measured before and after intervention as 
an indicator of successful passage of the supplement through gastrointestinal tract. Statistical 
analysis: Intention-to-treat (ITT) analysis was performed on all participants, while per-
protocol (PP) analysis was performed on those participants who had successfully completed 
the trial with good compliance rate. Results: With respect to primary outcomes, glycated 
hemoglobin decreased by 0.14 % in the probiotics and increased by 0.02 % in the placebo 
group in PP analysis (p < 0.05, small effect size of 0.050), while these changes were not 
significant in ITT analysis. Fasting insulin increased by 1.8 µU/mL in placebo group and 
decreased by 2.9 µU/mL in probiotics group in PP analysis. These changes were significant 
between groups at both analyses (p < 0.05, medium effect size of 0.062 in PP analysis and 
small effect size of 0.033 in ITT analysis). Secondary outcomes did not change significantly. 
Probiotics successfully passed through the gastrointestinal tract. Conclusion: Probiotics 
modestly improved HbA1c and fasting insulin in people with type 2 diabetes. 
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